GENTILIN, Erica
 Distribuzione geografica
Continente #
NA - Nord America 3.313
EU - Europa 878
AS - Asia 532
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
AF - Africa 1
OC - Oceania 1
Totale 4.732
Nazione #
US - Stati Uniti d'America 3.310
CN - Cina 323
UA - Ucraina 209
DE - Germania 154
IT - Italia 141
PL - Polonia 136
TR - Turchia 126
GB - Regno Unito 99
SG - Singapore 71
SE - Svezia 63
FI - Finlandia 54
BE - Belgio 12
ID - Indonesia 5
RU - Federazione Russa 5
VN - Vietnam 5
CA - Canada 3
EU - Europa 3
BR - Brasile 2
FR - Francia 2
CL - Cile 1
EC - Ecuador 1
ES - Italia 1
IR - Iran 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
ZA - Sudafrica 1
Totale 4.732
Città #
Woodbridge 417
Fairfield 380
Chandler 323
Ashburn 303
Houston 298
Jacksonville 258
Ann Arbor 206
Seattle 155
Wilmington 142
Warsaw 136
Cambridge 120
Addison 83
Izmir 68
Beijing 62
Nanjing 60
Ferrara 56
Princeton 55
Boardman 46
Singapore 45
Milan 34
Shanghai 33
San Diego 29
Dearborn 24
Nanchang 24
Bremen 21
Shenyang 19
Washington 19
Changsha 17
Hebei 17
Mountain View 15
Jinan 14
Tianjin 14
Jiaxing 13
Brussels 11
Padova 11
Auburn Hills 9
Orange 9
Falls Church 8
New York 8
Tappahannock 8
Guangzhou 7
Indiana 7
Kunming 7
Norwalk 7
Redwood City 6
Dong Ket 5
Los Angeles 5
Bologna 4
Cagliari 4
Helsinki 4
Jakarta 4
Lanzhou 4
Leawood 4
London 4
Chengdu 3
Des Moines 3
Hefei 3
Munich 3
Ningbo 3
Rome 3
Taizhou 3
Walnut 3
Zhengzhou 3
Augusta 2
Kingston 2
San Francisco 2
Sassari 2
Taiyuan 2
Ardabil 1
Arezzo 1
Bekasi 1
Canaro 1
Changchun 1
Chisinau 1
Chongqing 1
Dongguan 1
Formia 1
Fuzhou 1
Genova 1
Hangzhou 1
Harbin 1
Islamabad 1
Kilburn 1
Knoxville 1
Lappeenranta 1
Las Cruces 1
Linares 1
Monmouth Junction 1
Muizenberg 1
Navegantes 1
Nürnberg 1
Redmond 1
Simi Valley 1
Southwark 1
Stra 1
Toronto 1
Tosagua 1
Wuhan 1
Xian 1
Yellow Springs 1
Totale 3.711
Nome #
Studio dell’azione del Mitotane, farmaco adrenolitico, sulla funzionalità ipofisaria 200
Igf-I influences everolimus activity in medullary thyroid carcinoma 158
Magmas Overexpression Inhibits Staurosporine Induced Apoptosis in Rat Pituitary Adenoma Cell Lines 157
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 131
Cyclin D1 levels are involved in the resistance to m-TOR inhibitors in human bronchial carcinoids 130
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors 129
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 125
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 124
Involvement of PKCβ and PKCδ isoforms in TSH signaling pathway in thyroid cancer cell lines 122
Functional characterization of a new deletion in CDKN1B 5'-UTR region 121
The cytotoxic effect of sunitinib on human bronchial carcinoid cell lines and primary cultures is counteracted by EGF and IGF-1 but not by VEGF 120
VEGF autocrine secretion is enhanced by EGFR activation trough ERK1/2 phosphorylation in human adrenocortical carcinoma cell lines 115
IGF-I Proliferative Effects Are Inhibited by Targeting PKC in Human Endocrine Tumor Cells 114
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 114
The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. 114
Magmas, a Gene Newly Identified as Overexpressed in Human and Mouse ACTH-Secreting Pituitary Adenomas, Protects Pituitary Cells from Apoptotic Stimuli 113
mTOR, p70S6K, AKT and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 108
Proto-oncogene PBF/PTTG1IP Regulates Thyroid Cell Growth and Represses Radioiodide Treatment 107
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 106
Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. 105
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 104
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells 103
Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines 100
Cushing in a Leaf: Endocrine Disruption From a Natural Remedy 96
null 92
Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. 92
PKCδ plays an important in regulating human medullary thyroid carcinoma cell viability 91
Growth hormone induces chemoresistance in breast cancer cells 90
Effects of mTOR inhibitors in the control of non functioning pituitary adenomas cell growth 85
null 81
Protein Kinase C: A Putative New Target for the Control of Human Medullary Thyroid Carcinoma Cell Proliferation in Vitro 80
Growth Hormone enhances breast cancer chemoresistance by protecting from apoptosis 77
GH enhances breast cancer chemoresistance by inhibiting JNK-mediated apoptosis 74
Differential mTOR and PI3K Pathway Activation in Human Bronchial Carcinoids 73
A Novel PKC beta II Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells 72
ctivation of EGFR promotes ACC cell proliferation by inducing VEGF autocrine secretion 68
Bronchial carcinoid response to mTOR inhibitors depends on mTOR expression levels 67
mTOR inhibitors hamper cell viability in selected human medullary thyroid carcinoma primary cultures 66
IGF-I proliferative effects are inhibited by targeting PKC in human neuroendocrine tumor cells 66
Targeting PKC in human pancreatic neuroendocrine tumor cells 65
GH protects breast cancer cells from chemotherapy by blocking cytotoxic-induced apoptosis in estrogen receptor negative breast cancer cells 64
miR-26a targets PRKCD in ACTH pituitary adenoma 60
miR-26a regulates cell cycle in ACTH-secreting pituitary adenomas through Protein Kinase C delta 54
MicroRNAs in the pituitary 53
Therapeutic concentrations of mitotane inhibit thyrotroph cell viability and TSH secretion in a mouse cell line model 52
mTOR inhibition influences cell viability of human bronchial carcinoids in vitro 52
PRKCD Is a Target of miR-26a in ACTH Pituitary Adenoma 51
Validation of a murine model to study deregulated pituitary microRNA 51
PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line 46
null 40
miR-26a and cell cycle control in ACTH secreting pituitary adenoma 31
CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids 27
miR-26a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase C  18
Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors 17
Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines 16
Protein kinase C delta mediates Pasireotide effects in an ACTH-secreting pituitary tumor cell line 4
Totale 4.791
Categoria #
all - tutte 18.096
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.096


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.080 166 39 36 163 75 135 94 101 83 121 42 25
2020/2021683 58 52 31 99 32 74 19 84 14 82 94 44
2021/2022504 26 37 31 7 22 31 22 17 15 50 53 193
2022/2023678 61 52 28 99 112 90 36 53 92 4 23 28
2023/2024357 32 36 25 11 39 56 15 69 4 3 3 64
2024/202527 27 0 0 0 0 0 0 0 0 0 0 0
Totale 4.791